Prompted by the observation that ICAM-1 is more highly expressed in tumor-infiltrating CD8+ T cells than in other immune cell populations 20, we hypothesized that ICAM-1 deficiency impairs the systemic antitumor effect of RT by disrupting antitumor T-cell immunity. The gene discussed is CD8A; the disease is neoplasm.